Price Action to Note: Today Asterias Biotherapeutics Inc Stock Rises

Price Action to Note: Today Asterias Biotherapeutics Inc Stock Rises

The stock of Asterias Biotherapeutics Inc (NYSEMKT:AST) is a huge mover today! The stock closed at $3.3 during the last session. It is down 32.65% since March 29, 2016 and is downtrending. It has underperformed by 36.13% the S&P500.
The move comes after 7 months positive chart setup for the $149.88M company. It was reported on Oct, 31 by We have $5.08 PT which if reached, will make NYSEMKT:AST worth $80.94M more.

Analysts await Asterias Biotherapeutics Inc (NYSEMKT:AST) to report earnings on November, 14. They expect $-0.20 earnings per share, down 53.85% or $0.07 from last year’s $-0.13 per share. After $-0.16 actual earnings per share reported by Asterias Biotherapeutics Inc for the previous quarter, Wall Street now forecasts 25.00% negative EPS growth.

Asterias Biotherapeutics Inc (NYSEMKT:AST) Ratings Coverage

Out of 3 analysts covering Asterias Biotherapeutics (NYSEMKT:AST), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Asterias Biotherapeutics has been the topic of 4 analyst reports since August 11, 2015 according to StockzIntelligence Inc. As per Tuesday, August 11, the company rating was maintained by MLV. FBR Capital initiated it with “Outperform” rating and $10 target price in Thursday, November 19 report. The firm has “Hold” rating by Zacks given on Thursday, September 3. The company was initiated on Monday, May 23 by Chardan Capital Markets.

According to Zacks Investment Research, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California.”

More notable recent Asterias Biotherapeutics Inc (NYSEMKT:AST) news were published by: which released: “Asterias Biotherapeutics Appoints Stephen L. Cartt President and Chief …” on February 29, 2016, also with their article: “Asterias Biotherapeutics Announces Dosing of First Patient in New SCiSTAR …” published on September 27, 2016, published: “Asterias Biotherapeutics Appoints Ryan Chavez as EVP of Finance and General …” on July 18, 2016. More interesting news about Asterias Biotherapeutics Inc (NYSEMKT:AST) were released by: and their article: “Asterias Biotherapeutics Announces Record Date for Distribution of Warrants to …” published on March 31, 2016 as well as‘s news article titled: “Asterias Biotherapeutics Announces Successful End-of-Phase 2 Meeting with FDA …” with publication date: February 24, 2016.

AST Company Profile

Asterias Biotherapeutics, Inc., incorporated on October 24, 2012, is a biotechnology company. The Firm is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Firm has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. The Firm is focused on developing therapies to treat conditions with medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient’s own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with its collaboration partner, Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells which could provide off the shelf cells that teaches a patient’s immune system to recognize and fight cancer cells, in non-small cell lung cancer. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells, in an initial clinical indication of spinal cord injury, with potential for later expansion into other neurodegenerative diseases, such as stroke and multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment